The following are some of the clients that have benefited from DDO’s consultancy services:
Beactica is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a robust reputation as a leader in SPR-based drug discovery. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes.
Xention is a Cambridge, UK-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation and overactive bladder in clinical development as well as preclinical research programmes focused on other ion channel targets in atrial fibrillation and autoimmune disease.
Union Life Sciences (ULS) is a recently formed company, which focuses on the scientific and commercial development of early stage, world beating biology from Universities throughout Europe. Union Life Sciences has been established to: In-license pioneering biological research (typically around a therapeutic target/ target family); Work with the licensor to enhance the research programme by adding chemistry and advancing the resulting compounds through the early stages of drug discovery; License the enriched product to industrial partners.
ZA Biotech (Pty) Ltd is a private company based in Pretoria, South Africa. It is a joint venture between the Biotechnology Partnership and Development (BioPAD), and the Council for Scientific and Industrial Research (CSIR) through its Biosciences unit. The company is building a portfolio of intellectual property and technology in the Biosciences domain based on CSIR and external sources. Partnering and licensing form a core component of ZA Biotech’s strategy.
De Novo Pharmaceuticals is a world leader in in-silico, de novo drug design. De Novo’s technology is derived from a substantial body of research over thirty years in the Department of Pharmacology at the University of Cambridge. The core technology, SkelGen®, provides rapid access to novel hits through exploration of trillions of drug-like molecules.